



T

**FULBRIGHT & JAWORSKI L.L.P.**

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

01370

GSHISHIMA@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

September 23, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Box Sequence, P. O. Box 2327, Arlington, VA 22202, on the date below:	
<u>September 23, 2002</u> Date	 Gina N. Shishima

Commissioner for Patents  
Washington, DC 20231

RE: *SN 09/841,720 "MU OPIOID RECEPTOR METHODS (as amended)" - by Yu*  
*Our ref: INDA:002USD1/10103856*

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence Disclosures;
- (2) Statement as Required Under 37 C.F.R. §1.85(a) and (b) and as Required Under 37 C.F.R. §1.821(g) (with paper copy and computer readable copy of sequence listing); and
- (3) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/INDA:002USD1.

Respectfully submitted,

Gina N. Shishima  
Reg. No. 45,104

:lb  
Encl.: As stated

25121015.1